Key facts
- Cannasoul Analytics’s last known valuation is $16.0M (Nov 2023).
- It has raised $4.0M; the latest was Later Stage VC in Nov 2025.
- Notable investors include InterCure, TAO Synergies.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Cannasoul Analytics
- ·The full record, as it builds
Funding rounds
No funding rounds for Cannasoul Analytics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cannasoul Analytics
Operator of a drug discovery company intended to develop botanical medicine and therapeutics derived from natural compounds. The company offers cannabis molecular analysis, clinical and pre-clinical trials, and research and development (R&D) and engages in the screening of cannabis and psilocybin extracts, isolated cannabinoids, and novel molecules on various cell line models, enabling researchers to bridge the gap between botanical medicine and the pharmaceutical industry.
- Sector
- Healthcare
- HQ
- Caesarea, Israel
- Founded
- 2018
- Employees
- 16
- Website
- cannasoul.co.il/
- Ownership
- Privately Held (backing)
Cannasoul Analytics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cannasoul Analytics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cannasoul Analytics in its N-PORT filings yet. We sweep new filings monthly.